Optimus Receives Tentative Approval from U.S. FDA for Brexpiprazole Tablets

Hyderabad (Telangana) [India], October 09: Optimus Pharma Private Limited today announced that it has received tentative approval from the United States Food and Drug Administration (FDA) for the generic equivalent of Rexulti® Tablets, 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, and 4 mg, of Otsuka Pharmaceutical Co., Ltd. Optimus Pharma’s approval for its Abbreviated New Drug Application (ANDA) BREXPIPRAZOLE Tablets, 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, and 4 mg, was received on October 8th, 2021. BREXPIPRAZOLE will be manufactured at Optimus Pharma’s Pashmylaram USFDA accredited facility in India.

BREXPIPRAZOLE Tablets (RLD: Rexulti® Tablets) had estimated annual sales of USD 1258 million in the U.S. (IQVIA MAT July 2021).

BREXPIPRAZOLE has a favourable antipsychotic profile in terms of improvement of cognitive performance and sleep patterns, as well as effects on affective states and potential to treat core symptoms in schizophrenia and major depressive disorder, including cognitive deficits with a low risk of adverse effects (extrapyramidal symptoms, metabolic complications, weight gain, akathisia potential) that are commonly encountered with other typical and second-generation antipsychotic drugs. From the studies done so far, it can be concluded that BREXPIPRAZOLE can be effective monotherapy for schizophrenia and as an adjunct to other antidepressant medications in major depressive disorder.

About Optimus Pharma

Optimus was established in the year 2004 as a custom synthesis laboratory by a team of techno-commercial experts. It is one of the fastest-growing Manufacturer in Active Pharmaceutical Ingredients (APIs) and Finished dosages. Over the last decade, we have been certified and audited by reputed Global Regulatory Agencies like USFDA, WHO, COFEPRIS, EMA, KFDA and AFM from PMDA Japan. Optimus Pharma is a vertically integrated pharmaceutical company engaged in the manufacturing of Solid Oral and semisolid formulations. We have successfully integrated our API and Formulation R&D teams, with the IP and Regulatory Affairs team in order to ensure a dynamic product portfolio. We help our customers serve global markets with technology based, innovative, cost effective & consumer friendly products of the highest quality.

Related Posts

Markobenz Ventures Wins INR 1,400 Crore Road Contracts from Govt of India

New Delhi [India] September 9 : Markobenz Ventures Limited {BSE SCRIPT CODE :- 514060}, a leading infrastructure development company, is proud to announce that it has secured multiple road construction…

AICPE Education Awards 2024: Celebration of India’s Top Educators with Bollywood Icon Ritu Shivpuri

Nagpur (Maharashtra) [India] September 7: The AICPE Education Excellence Awards 2024 was a dazzling evening celebrating the dedication and contributions of educators from all corners of India. Organised by AICPE…

You Missed

Fayazoddin Mohamad – A Seasoned Expert in Regulatory Compliance and Pharmacy Management

  • September 9, 2024
Fayazoddin Mohamad – A Seasoned Expert in Regulatory Compliance and Pharmacy Management

“Delving into the depths of the human mind drives me to write” – Chirasree Bose

  • September 9, 2024
“Delving into the depths of the human mind drives me to write” – Chirasree Bose

Manglam Infra and Engineering Limited Secures Projects Worth Rs. 4.43 Crores

  • September 9, 2024
Manglam Infra and Engineering Limited Secures Projects Worth Rs. 4.43 Crores

Cut Down Your Electricity Bill with Bharat Smart Service’s AI-Powered Solutions!

  • September 7, 2024
Cut Down Your Electricity Bill with Bharat Smart Service’s AI-Powered Solutions!

Sundowner Festival: A Spectacular Two-Day Celebration of Music, Food, and Sunsets

  • September 7, 2024
Sundowner Festival: A Spectacular Two-Day Celebration of Music, Food, and Sunsets

Retail CFO Summit 2024: Bridging the Gap Between Retail CFOs and Solution Providers

  • September 7, 2024
Retail CFO Summit 2024: Bridging the Gap Between Retail CFOs and Solution Providers